Nuvation Bio outlines first-line IBTROZI growth strategy with 50-month median DOR amid expanding global partnerships [Seeking Alpha]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Seeking Alpha
David Hung, Founder, President, CEO & Chairman, highlighted that "2025 was a pivotal year for Nuvation Bio" due to the full U.S. FDA approval of IBTROZI for advanced ROS1-positive non-small cell lung cancer (NSCLC) on June 11, and the subsequent rapid Quick Insights Revenue growth is driven by increased new patient starts—especially first-line use—of IBTROZI in ROS1-positive NSCLC, the therapy's strong efficacy and safety, and expanding global partnerships. A shift from late-line to first-line patients improves revenue correlation with new patient starts, while high discontinuations in late-line patients currently moderate near-term revenue impact. Management asserts that, due to the strong cash position, there is no anticipated need for external financing before reaching profitability. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire
- Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NUVB) had its price target lowered by UBS Group AG from $10.00 to $7.00. They now have a "neutral" rating on the stock.MarketBeat
NUVB
Earnings
- 3/2/26 - In-Line
NUVB
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- NUVB's page on the SEC website